Sultopride is used in Japan, Hong Kong, and Europe to treat schizophrenia. It is of the drug class atypical antipsychotics L5626.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Ivabradine | Ivabradine may increase the QTc-prolonging activities of Sultopride. |
| Buprenorphine | Sultopride may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sultopride. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Sultopride. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Sultopride. |
| Hydrocodone | Sultopride may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Magnesium sulfate | The therapeutic efficacy of Sultopride can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | Sultopride may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | Sultopride may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Sultopride. |
| Mirtazapine | Sultopride may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Sultopride. |
| Orphenadrine | Sultopride may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | Sultopride may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Sultopride. |
| Rotigotine | Sultopride may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Sultopride. |
| Sodium oxybate | The risk or severity of CNS depression can be increased when Sodium oxybate is combined with Sultopride. |
| Suvorexant | Sultopride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Sultopride. |
| Thalidomide | Sultopride may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | Sultopride may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Amisulpride | Sultopride may increase the antipsychotic activities of Amisulpride. |
| Methylphenidate | The risk or severity of adverse effects can be increased when Sultopride is combined with Methylphenidate. |
| Dexmethylphenidate | The risk or severity of adverse effects can be increased when Sultopride is combined with Dexmethylphenidate. |
| Metoclopramide | The risk or severity of adverse effects can be increased when Metoclopramide is combined with Sultopride. |
| Quinagolide | The therapeutic efficacy of Quinagolide can be decreased when used in combination with Sultopride. |
| Sulpiride | Sultopride may increase the antipsychotic activities of Sulpiride. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with Sultopride. |
| Lithium citrate | Lithium citrate may increase the neurotoxic activities of Sultopride. |
| Lithium hydroxide | Lithium hydroxide may increase the neurotoxic activities of Sultopride. |
| Mequitazine | Sultopride may increase the arrhythmogenic activities of Mequitazine. |
| Dicoumarol | The risk or severity of adverse effects can be increased when Sultopride is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when Sultopride is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when Sultopride is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when Sultopride is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when Sultopride is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when Sultopride is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when Sultopride is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when Sultopride is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when Sultopride is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when Sultopride is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when Sultopride is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when Sultopride is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when Sultopride is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when Sultopride is combined with (S)-Warfarin. |
| Ethanol | Sultopride may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | Sultopride may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Sultopride. |
| Zimelidine | The risk or severity of adverse effects can be increased when Sultopride is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when Sultopride is combined with Dapoxetine. |
| Seproxetine | The risk or severity of adverse effects can be increased when Sultopride is combined with Seproxetine. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when Sultopride is combined with Fluvoxamine. |
| Duloxetine | The risk or severity of adverse effects can be increased when Sultopride is combined with Duloxetine. |
| Paroxetine | The risk or severity of adverse effects can be increased when Sultopride is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when Sultopride is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when Sultopride is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when Sultopride is combined with Nefazodone. |
| Milnacipran | The risk or severity of adverse effects can be increased when Sultopride is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Sultopride is combined with Desvenlafaxine. |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Levomilnacipran is combined with Sultopride. |
| Indalpine | The risk or severity of adverse effects can be increased when Sultopride is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when Sultopride is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when Sultopride is combined with Alaproclate. |
| Cyproheptadine | The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Sultopride. |
| Propiomazine | The risk or severity of CNS depression can be increased when Propiomazine is combined with Sultopride. |
| Zopiclone | The risk or severity of adverse effects can be increased when Sultopride is combined with Zopiclone. |
| Eletriptan | The risk or severity of adverse effects can be increased when Eletriptan is combined with Sultopride. |
| Cabergoline | The risk or severity of adverse effects can be increased when Cabergoline is combined with Sultopride. |
| Zolmitriptan | The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Sultopride. |
| Meperidine | The risk or severity of adverse effects can be increased when Meperidine is combined with Sultopride. |
| Dextromethorphan | The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Sultopride. |
| Mazindol | The risk or severity of adverse effects can be increased when Mazindol is combined with Sultopride. |
| Linezolid | The risk or severity of adverse effects can be increased when Linezolid is combined with Sultopride. |
| Sumatriptan | The risk or severity of adverse effects can be increased when Sumatriptan is combined with Sultopride. |
| Ergotamine | The risk or severity of adverse effects can be increased when Ergotamine is combined with Sultopride. |
| Fentanyl | The risk or severity of adverse effects can be increased when Fentanyl is combined with Sultopride. |
| Almotriptan | The risk or severity of adverse effects can be increased when Almotriptan is combined with Sultopride. |
| Naratriptan | The risk or severity of adverse effects can be increased when Naratriptan is combined with Sultopride. |
| Rizatriptan | The risk or severity of adverse effects can be increased when Rizatriptan is combined with Sultopride. |
| Frovatriptan | The risk or severity of adverse effects can be increased when Frovatriptan is combined with Sultopride. |
| Procarbazine | The risk or severity of adverse effects can be increased when Procarbazine is combined with Sultopride. |
| Bromocriptine | The risk or severity of adverse effects can be increased when Bromocriptine is combined with Sultopride. |
| Ergometrine | The risk or severity of adverse effects can be increased when Ergometrine is combined with Sultopride. |
| Rasagiline | The risk or severity of adverse effects can be increased when Rasagiline is combined with Sultopride. |
| Lorcaserin | The risk or severity of adverse effects can be increased when Lorcaserin is combined with Sultopride. |
| Etoperidone | The risk or severity of adverse effects can be increased when Etoperidone is combined with Sultopride. |
| Lorpiprazole | The risk or severity of adverse effects can be increased when Lorpiprazole is combined with Sultopride. |
| Amphetamine | Sultopride may decrease the stimulatory activities of Amphetamine. |
| Phentermine | Sultopride may decrease the stimulatory activities of Phentermine. |
| Pseudoephedrine | Sultopride may decrease the stimulatory activities of Pseudoephedrine. |
| Benzphetamine | Sultopride may decrease the stimulatory activities of Benzphetamine. |
| Diethylpropion | Sultopride may decrease the stimulatory activities of Diethylpropion. |
| Lisdexamfetamine | Sultopride may decrease the stimulatory activities of Lisdexamfetamine. |
| Mephentermine | Sultopride may decrease the stimulatory activities of Mephentermine. |
| MMDA | Sultopride may decrease the stimulatory activities of MMDA. |
| 2,5-Dimethoxy-4-ethylamphetamine | Sultopride may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine. |
| Chlorphentermine | Sultopride may decrease the stimulatory activities of Chlorphentermine. |
| Methylenedioxyethamphetamine | Sultopride may decrease the stimulatory activities of Methylenedioxyethamphetamine. |
| Dextroamphetamine | Sultopride may decrease the stimulatory activities of Dextroamphetamine. |